English

BioStock: CombiGene comments on their latest progress

Report this content

Last week, CombiGene reported that the company’s two warrants were exercised at 98.4 percent, which thus added just over SEK 25 million to the company. In addition, one of the company’s co-founders, Associate Professor David Woldbye, published a peer-reviewed article in Frontiers in Molecular Neuroscience, concerning CombiGene’s epilepsy project CG01. BioStock reached out to CEO Jan Nilsson for a comment.

Read the full interview with CombiGene's CEO Jan Nilsson at  biostock.se: 

https://www.biostock.se/en/combigene-comments-on-their-latest-progress/

This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

 
 

Subscribe

Documents & Links

Quick facts

BioStock: CombiGene comments on their latest progress
Tweet this

Quotes

The importance of having access to future-proof production is illustrated, among other things, by Bayer’s acquisition of AskBio and their advanced production method, and this is precisely the production method we have access to through our agreement with Viralgen, which was originally founded by AskBio. All in all, the activities we carried out during the year have significantly moved our positions forward
Jan Nilsson, CEO CombiGene